Holen Sie sich die Stockscreener-App
31.32
1.83%
0.455
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital - AD HOC NEWS
Indivior Prices Upsized Convertible Notes for Debt Refinancing - TipRanks
Indivior (INDV) Upsizes Convertible Notes Offering to $450M - GuruFocus
Indivior Pharmaceuticals prices upsized $450M convertible senior notes - MSN
Indivior plans $400 million convertible notes offering By Investing.com - Investing.com India
Indivior (INDV) Plans $400 Million Convertible Notes Offering - GuruFocus
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - The Manila Times
Indivior prices $450 million convertible notes offering - Investing.com
Indivior Pharmaceuticals Announces Pricing of $450 Million Convertible Senior Notes Offering - Quiver Quantitative
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Indivior plans $400 million convertible notes offering - Investing.com Nigeria
Indivior proposes $400M convertible senior notes due 2031 to refinance debt, fund buybacks - TradingView
Indivior plans $400M convertible senior notes offering - MSN
Indivior Announces $400 Million Convertible Notes and Buyback - TipRanks
Indivior stock falls after convertible notes offering announced - Investing.com
Indivior Announces Proposed Convertible Senior Notes Offering - Yahoo Finance UK
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares - MarketBeat
Indivior director Kingsley buys $29,953 in shares - Investing.com
Insider Buying: Barbara Ryan Acquires Shares of Indivior Pharmac - GuruFocus
Indivior (INDV) Study: Sublocade Reduces Healthcare Costs for OU - GuruFocus
New Study Shows Adherence to Monthly Injectable - GlobeNewswire
Ryan Barbara buys Indivior (INDV) shares worth $1,009 - Investing.com South Africa
Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV - MarketBeat
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Earnings Growth And New US$400 Million Buyback - Sahm
Claret Asset Management Corp Has $18.92 Million Stake in Indivior PLC $INDV - MarketBeat
Implied Volatility Spikes for Indivior Pharmaceuticals Equity Options - Bitget
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options - TradingView
Jefferies Financial Group Inc. Has $17.05 Million Stock Holdings in Indivior PLC $INDV - MarketBeat
How Strong Q4 Results, Reaffirmed 2026 Outlook and New Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Indivior (INDV) Q4 2025 Earnings Call Transcript - AOL.com
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its Recent Pullback In Price? - simplywall.st
Vanguard Group Inc. Has $83.10 Million Holdings in Indivior PLC $INDV - MarketBeat
Global Transdermal Skin Patch Market Size, Growth, Trends & - openPR.com
Royce & Associates LP Buys Shares of 246,524 Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Indivior Pharmaceuticals, Inc. (INDV): Investor Outlook With 45% Potential Upside - DirectorsTalk Interviews
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Equities Analysts Issue Forecasts for Indivior Q4 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for Indivior Earnings - MarketBeat
Indivior Pharmaceuticals (INDV) Valuation Check After Strong Long Term Shareholder Returns - Sahm
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV) - simplywall.st
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT I - GuruFocus
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change - Yahoo Finance
Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Indivior (NASDAQ:INDV) Announces Earnings Results - MarketBeat
INDVIndivior Pharmaceuticals Inc. Latest Stock News & Market Updates - Stock Titan
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Sector Update: Health Care - marketscreener.com
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises - Investing.com Nigeria
Indivior Q4 Earnings Call Highlights - Yahoo Finance
Indivior Q4 2025 slides: SUBLOCADE momentum drives earnings beat By Investing.com - Investing.com UK
Indivior's Q4 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q4 Revenue $358.0M, vs. FactSet Est of $305.6M - marketscreener.com
Indivior Reports Record 2025 Results, Launches Share Buyback - TipRanks
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.82 per Share, vs. FactSet Est of $0.67 - marketscreener.com
Indivior Plc. Reports Increase In Q4 Bottom Line - Nasdaq
Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck - marketscreener.com
Indivior Pharmaceuticals : FINAL Press Release - marketscreener.com
Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck - marketscreener.com
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
Indivior Returns to Havas With U.S. AOR Assignment - ADWEEK
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Strong Buy Ratings and 38% Upside Potential - DirectorsTalk Interviews
0.86%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):